$VRSK

Shavel Lee sold $550K of VRSK

Shavel Lee (Chief Executive Officer) sold 2,500 shares of Verisk Analytics, Inc. (VRSK) at $220.00 ($0.55M total) on 2026-07-29 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Shavel Lee
Published Jul 31, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 31, 2026, 8:28 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$VRSK
Neutral
high confidence
Mentioned
$VRSK
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$VRSKNeutralLow
01

Why it matters

Because the text contains no new business, financial, or regulatory information beyond the transaction mechanics, the trading impact should be limited to sentiment and positioning rather than fundamentals.

02

Market read

Traders may note the insider sale for sentiment, but there is no new catalyst to drive a durable repricing.

03

What to watch

The article provides only the sale details; it does not include total planned volume, prior sales cadence, or whether other insiders bought/sold around the same period.

Relevance 4/10Novelty 3/10Timing: Filed on 2026-07-31 after-hours; reflects sale executed 2026-07-29.

Background

The article is a SEC Form 4 insider transaction for Verisk Analytics, reporting an open-market sale by the CEO under a pre-arranged 10b5-1 plan.

Company-level read

Ticker impact

$VRSKNeutralHigh confidence
Context

Verisk CEO Shavel Lee filed a Form 4 open-market sale of 2,500 shares at $220 on 2026-07-29 under a 10b5-1 plan.

Expected impact

Low near-term impact; any reaction is likely limited to short-lived sentiment noise.

Evidence & confidence

The filing is an open-market sale under a pre-arranged 10b5-1 plan, with no accompanying guidance, deal, or regulatory development in the text.

Market effects

Minimal, as the disclosure is company-specific and does not indicate sector-wide regulatory or demand changes.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can be read by some traders as a mild confidence signal, especially if paired with other negative news not present here.

Key entities

  • Verisk Analytics, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Shavel Lee

    CEO and director who executed the reported open-market sale under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$VRSKMed

VRSK Maintained by Barclays -- Price Target Lowered to $225

Barclays maintained an Overweight rating on Verisk Analytics (VRSK) but lowered its price target from $275 to $225. The company's stock is trading at $179.17, which GuruFocus estimates is 44.4% undervalued. Verisk has a GF Score of 78/100, indicating strong profitability and growth, but lower momentum. Insider activity shows significant selling, with $2.55 million in sales over the past three months.

$VRSKMed

Is Verisk’s Q2 Beat, Buyback and AI Push Altering The Investment Case For Verisk Analytics (VRSK)?

Verisk Analytics (VRSK) reported Q2 2026 earnings and revenue above estimates, reaffirmed its 2026 outlook, and announced a $200M share repurchase. The company emphasized growth in AI and data analytics for insurance clients. Verisk projects $3.8B in revenue and $1.3B in earnings by 2029, with a 24% upside to its current price. The company's high debt levels and interest expenses remain key risks.

$VRSKMedAI 8/10

Verisk (VRSK) Down 4.7% Since Last Earnings Report: Can It Rebound?

Verisk (VRSK) shares fell 4.7% since its last earnings report. Q2 2026 earnings beat estimates at $1.98 per share, up 5.3% YoY. Revenue rose 4.3% to $806.3M. Underwriting and claims revenues increased 3.5% and 6.3% respectively. EBITDA grew 4.2% but net income declined 9.8% due to higher taxes and interest. The company maintained 2026 guidance and approved a dividend. Estimates have trended downward, with a Zacks Rank #3 (Hold).

$VRSKMedAI 8/10

Verisk Analytics v. AccuLynx: Sorry, You Actually DO Have To Comply With That Second Request

The Delaware Court of Chancery ordered Verisk Analytics to continue pursuing FTC clearance for its $2.35 billion acquisition of AccuLynx, despite Verisk's attempt to terminate the deal. The court ruled that Verisk's termination was invalid due to its willful conduct in ending negotiations with a competitor, ServiceTitan. Verisk must now comply with a costly Second Request process, which typically takes many months to complete. The court's decision is notable as it is the first to compel a buyer